GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mind Medicine Inc (OTCPK:MMCWF) » Definitions » EV-to-FCF

Mind Medicine (Mind Medicine) EV-to-FCF : 0.00 (As of May. 12, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Mind Medicine EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Mind Medicine's Enterprise Value is $0.00 Mil. Mind Medicine's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-64.37 Mil. Therefore, Mind Medicine's EV-to-FCF for today is 0.00.

The historical rank and industry rank for Mind Medicine's EV-to-FCF or its related term are showing as below:

MMCWF' s EV-to-FCF Range Over the Past 10 Years
Min: -32.67   Med: 0   Max: 0.37
Current: -9.01

During the past 4 years, the highest EV-to-FCF of Mind Medicine was 0.37. The lowest was -32.67. And the median was 0.00.

MMCWF's EV-to-FCF is ranked worse than
100% of 390 companies
in the Biotechnology industry
Industry Median: 6.365 vs MMCWF: -9.01

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-12), Mind Medicine's stock price is $0.0677. Mind Medicine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.000. Therefore, Mind Medicine's PE Ratio for today is N/A.


Mind Medicine EV-to-FCF Historical Data

The historical data trend for Mind Medicine's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mind Medicine EV-to-FCF Chart

Mind Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-FCF
-36.25 -9.78 1.17 -1.01

Mind Medicine Quarterly Data
Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.17 0.16 -0.44 -0.39 -1.01

Competitive Comparison of Mind Medicine's EV-to-FCF

For the Biotechnology subindustry, Mind Medicine's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mind Medicine's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mind Medicine's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Mind Medicine's EV-to-FCF falls into.



Mind Medicine EV-to-FCF Calculation

Mind Medicine's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=0.000/-64.365
=0.00

Mind Medicine's current Enterprise Value is $0.00 Mil.
Mind Medicine's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-64.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mind Medicine  (OTCPK:MMCWF) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Mind Medicine's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0677/0.000
=N/A

Mind Medicine's share price for today is $0.0677.
Mind Medicine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Mind Medicine EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Mind Medicine's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Mind Medicine (Mind Medicine) Business Description

Traded in Other Exchanges
Address
One World Trade Center, Suite 8500, New York, NY, USA, 10007
Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies.